Comparaciones Financieras Zentalis Pharmaceuticals, Inc.
Acciones
ZNTL
US98943L1070
Biotecnología e investigación médica
Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
2,960 USD | -8,64 % | -14,70 % | -80,46 % |
20/08 | Radiopharm Theranostics nombra a Dimitris Voliotis director médico | CI |
09/08 | Las pérdidas del 2T de Zentalis Pharmaceuticals se reducen; las acciones caen | MT |
Añadir a una lista 0 seleccionado | Ventas netas ($) (Y-1) | Margen neto (Y-1) | Margen Operativo (Y-1) | ROE (Y-1) | ROA (Y-1) | Apalancamiento (Dette/EBITDA) (Y-1) | |
---|---|---|---|---|---|---|---|
13,12 mil M | +30.14% | +39.08% | +20.74% | +16.20% | -1.6x | ||
9869,2 M | +36.68% | +44.33% | +22.99% | +17.71% | -2.46x | ||
1300,15 M | -23.26% | -33.51% | -8.54% | -7.69% | 10.14x | ||
4240,51 M | +24.36% | +18.08% | +4.62% | +4.02% | -13.1x | ||
2458,78 M | -35.86% | -49.12% | -22.26% | -14.47% | 2.05x | ||
2451,79 M | +26.42% | +32.30% | +14.78% | +13.31% | -5.01x | ||
5691,1 M | +26.50% | +29.43% | +18.99% | +15.45% | -0.64x | ||
1243,34 M | -43.11% | -21.54% | -86.15% | -1.86% | 1.96x | ||
305 M | -245.59% | -232.51% | - | -50.20% | -0.8x | ||
1887,1 M | +13.23% | +13.30% | +12.68% | +8.89% | -5.76x | ||
285 M | -181.75% | -144.69% | -51.94% | -32.60% | 2.5x | ||
51,02 M | -205.30% | -166.94% | -58.43% | - | 2.98x | ||
829 M | +33.96% | +40.71% | +293.15% | +20.80% | 2.73x | ||
1830,21 M | +11.35% | +9.34% | +8.74% | +6.91% | -5.06x | ||
160 M | -12.22% | -37.48% | -3.46% | -2.93% | 11.91x | ||
296 M | -180.51% | -170.79% | -818.43% | -50.27% | -0.33x | ||
Promedio | 2876 M | -45,31 % | -39,38 % | -43,50 % | -3,78 % | -0,03x | |
Media ponderada por Capi. | 7334,32 M | +0,63 % | +6,26 % | +0,01 % | +7,45 % | -1,02x |
- Bolsa de valores
- Acciones
- Acción ZNTL
- Sector Zentalis Pharmaceuticals, Inc.
- Comparaciones Financieras
MarketScreener is also available in this country: United States.
Switch edition